U.S. markets closed
  • S&P Futures

    3,295.50
    +32.00 (+0.98%)
     
  • Dow Futures

    26,664.00
    +255.00 (+0.97%)
     
  • Nasdaq Futures

    11,238.25
    +105.50 (+0.95%)
     
  • Russell 2000 Futures

    1,552.10
    +12.90 (+0.84%)
     
  • Crude Oil

    37.42
    +0.03 (+0.08%)
     
  • Gold

    1,880.60
    +1.40 (+0.07%)
     
  • Silver

    23.48
    +0.12 (+0.50%)
     
  • EUR/USD

    1.1754
    +0.0004 (+0.04%)
     
  • 10-Yr Bond

    0.7810
    +0.0030 (+0.39%)
     
  • Vix

    40.28
    +6.93 (+20.78%)
     
  • GBP/USD

    1.2998
    +0.0011 (+0.08%)
     
  • USD/JPY

    104.4670
    +0.1660 (+0.16%)
     
  • BTC-USD

    13,235.13
    +17.84 (+0.14%)
     
  • CMC Crypto 200

    262.00
    -10.69 (-3.92%)
     
  • FTSE 100

    5,582.80
    -146.19 (-2.55%)
     
  • Nikkei 225

    23,261.98
    -156.53 (-0.67%)
     

TransUnion (TRU) Jumps: Stock Rises 7.8%

Zacks Equity Research
·2 mins read

TransUnion TRU was a big mover last session, as the company saw its shares rise nearly 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $54.98 to $72.34 in the past one-month time frame.

The company has seen four negative estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks, suggesting there may be trouble down the road. So, make sure to keep an eye on this stock going forward, to see if this recent move higher can last.

TransUnion currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.

TransUnion Price

TransUnion Price
TransUnion Price

TransUnion price | TransUnion Quote

Investors interested in the Business Services sector may consider FTI Consulting, Inc. FCN, which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
FTI Consulting, Inc. (FCN) : Free Stock Analysis Report
 
TransUnion (TRU) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.